Generics makers ask SCOTUS to let them proceed with Copaxone copies

Teva ($TEVA) wants generics makers to hold off on launching their copies of multiple sclerosis drug Copaxone until the Supreme Court hears its appeal in a patent fight over the drug. And unsurprisingly, those generics companies are not that into the idea. Two knockoff teams--Novartis' ($NVS) Sandoz and Momenta Pharmaceuticals ($MNTA), and Mylan ($MYL) and India's Natco Pharma--responded to the Israeli drugmaker's stay application Monday, asking SCOTUS to let them go forward with their copies. And now that they've responded, the high court can announce at any time whether it will grant Teva's request. Story | More

Suggested Articles

Not even two months into a probe of officials accused of taking Novartis bribes, Greece's parliament is handing off the investigation.

A U.S. appeals court called Maryland's groundbreaking price-hike law unconstitutional, sending legislators back to the drawing board.

Novartis CEO Vas Narasimhan has joined the chorus calling for the U.S. to step up on biosimilar market access, stat.